Buenos Aires, Argentina (UroToday.com) Antonio Finelli, Associate Professor, University of Toronto discussed debate regarding biopsies in small renal masses (SRMs).Up to 25% SRMs are benign with recent meta-analyses of over 1500 articles with over 3000 patients have shown minimal complications <0.1% associated with biopsies.
Accuracy is approximately 90% with careful distinction between core biopsies and fine needle biopsy with the former being more accurate. While some argue renal biopsy will not alter treatment Dr. Finelli argue it can due to identification of benign histology such as Type I papillary renal cell carcinoma which may be observed. Concordance with surgery is over 90% comparing biopsy to final surgical pathology among those that undergo definitive surgery. Moreover, with the advent of proteomic and genomic evaluation of tumors research have shown that core biopsies can be banked for future research purposes with data at their institution demonstrating sufficient tissue available in the biopsies for that purpose.
World Urological Oncology Federation Symposium at the SIU Congress 2016 - October 20 - 23, 2016 – Buenos Aires, Argentina
Written By: Stephen B. Williams, M.D., Assistant Professor in Urology, The University of Texas Medical Branch, Galveston, TX. and Ashish Kamat, M.D. Professor, Department of Urology, Division of Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX.